Myriad Genetics, Inc. MYGN recently made SneakPeek available over the counter in more than 8,800 retail locations nationwide.

The firms said that the deal will provide access to Tempus' testing menu for healthcare providers at 800 cancer care locations that use Flatiron's OncoEMR platform.

Myriad Genetics and agency partner S50 Health educated OBGYNs and their patients in a campaign called “Getting Ahead of ...

盐湖城 - 专门从事基因测试和精准医疗的Myriad Genetics, Inc. (NASDAQ: MYGN)宣布对联合健康最近的政策更新表示不同意。该保险公司计划从2025年1月1日起，在其商业和个人交换福利计划下限制多基因组药物基因组学测试的覆盖范围，包括Myriad的GeneSight测试。 这一政策变更于周五传达给Myriad，公司对此表示惊讶和失望。Myriad的总裁兼首席执行官Pau ...

Out of the 30 companies tracked by 360Dx, 22 saw their share prices decline, seven saw their stock prices increase, and one company’s shares remained essentially flat.

Adam Brufsky, MD, PhD, professor of medicine at the University of Pittsburgh School of Medicine; Megan Kruse, MD, breast medical oncologist at Cleveland Clinic; and Ruta Rao, MD, professor of medicine ...

Myriad Genetics (MYGN) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus ...

Weakness in the industrial market sector and the EMEA region are concerning. Myriad Genetics (MYGN) Banks on MyRisk Test, Cost Woes Stay Per the Zacks analyst, expanded guidelines and acceleration ...